Health

Study protocol for assessing the user acceptance, safety and efficacy of a tabletbased workflow and decision support system with incorporated basal insulin algorithm for glycaemic management in participants with type 2 diabetes receiving home health care

Publikation aus Health
Kompetenzgruppe Klinische Entscheidungsunterstützung

Angela Libiseller, Julia Kopanz, Katharina M. Lichtenegger, Julia K. Mader, Thomas Truskaller, Bettina Lackner, Felix Aberer, Marlene Pandis, Johanna Reinisch-Gratzer, Gisela C. Ambrosch, Frank Sinner, Thomas R. Pieber, Klaus Donsa

Contemporary Clinical Trials Communications , 9/2020

Abstract:

Introduction

Diabetes management can be especially complex for older adults who receive health care at home. Thus, international guidelines recommend basal-insulin regimens due to simpler handling and low hypoglycaemia risk. A basal-insulin algorithm (including basal-plus) was developed to also include participant's health status and subsequently implemented into a tablet-based workflow and decision support system, GlucoTab@MobileCare. This study protocol describes a proof-of-concept study to investigate user acceptance, safety and efficacy of the GlucoTab@MobileCare system in participants receiving home health care.

 

Methods

The open-label, single-centre, uncontrolled study will recruit a maximum of ten participants with insulin treated type-2-diabetes (age ≥18 years) who receive home health care. During a three month study period participants will receive basal- or basal-plus-insulin therapy once daily as suggested by the GlucoTab@MobileCare system. Statistical analysis will be conducted on an intention-to-treat basis. The primary endpoint is the percentage of tasks (BG measurements, insulin dose calculations, insulin injections) that were performed according to GlucoTab@MobileCare suggestions relative to the total of suggested tasks. Secondary endpoints include user acceptance, safety and efficacy parameters. The study was approved by the ethics committee and regulatory authorities. Before obtaining written informed consent, all participants will receive oral and written information about all aspects of the study. Results will be published in a peer-reviewed journal and at diabetes and geriatric conferences.

 

Discussion

Potential implications may be improved quality and safety of basal-insulin therapy in older adults as well as support for health-care-providers in daily routine including evidence-based knowledge.

Keywords: Clinical trials Elderly Devices Insulin therapy Diabetes

Url: https://www.sciencedirect.com/science/article/pii/S2451865420301046